Anavex Life Sciences Corp (AVXL)

[Bud Powell]

I guess the advisor panel is just a formality. From the article, "10 of 11 [on the panel] found that there was not enough evidence to show it could slow cognitive decline. The 11th voted “uncertain.” ... But the FDA still approved the treatment on Monday." WTF? Hats off to Mr. Perlmutter.

Neurologist Joel Perlmutter of Washington University in St. Louis, a member of the FDA’s expert panel for nervous system therapies, told STAT in an email that he had quit the committee on Monday “due to this ruling by the FDA without further discussion with our advisory committee.”